On March 20, 2026, the U.S. Food and Drug Administration (FDA) issued a significant safety communication requiring the addition of a new warning to all carbidopa/levodopa-containing drug products. These medications, used to treat symptoms of Parkinson's disease, can cause vitamin B6 deficiency and, in some cases, vitamin B6 deficiency-associated seizures.
This comprehensive review examines the pharmacovigilance landscape of major GI drug classes, including proton pump inhibitors (PPIs), prokinetic agents (domperidone, metoclopramide), sphingosine-1-phosphate (S1P) receptor modulators, and small molecule drugs for inflammatory bowel disease (IBD).
Drug-induced gynaecomastia, safety updates on empagliflozin and Fournier's gangrene, tolerability of zoledronic acid in elderly patients, emerging concerns with GLP-1 receptor agonists, and recent regulatory changes under the Medicines Amendment Act 2025.
The signals include a new aspect of a known risk (aseptic meningitis with chikungunya vaccine), a rare but serious adverse event (acquired haemophilia with omalizumab), and a routine pharmacovigilance recommendation (pemphigoid with risankizumab).
The National Institute for Health and Care Excellence (NICE) guideline NG28, updated in 2026, provides comprehensive recommendations for healthcare professionals on selecting, reviewing, and modifying glucose-lowering therapies in adults with type 2 diabetes.
The most common diseases affecting women, their causes, and the critical role of pharmacovigilance in ensuring medication safety. We explore drug-induced conditions that disproportionately affect women, evidence-based treatment strategies, and age-specific preventive measures.
Presents critical safety information for healthcare professionals, including a label update on drug‑induced aseptic meningitis, a local case report of excessive infant sleep following maternal escitalopram use during breastfeeding, and updates on EPVC educational and awareness initiatives.
Advancing Medication Safety Through Knowledge and Vigilance
